19 May 2013
Keywords: role, mir-21, regulating, certain, cancer, cells, regulus
Article | 01 September 2008
Regulus Therapeutics, a joint venture between US RNAi specialists Alnylam and Isis, say that new data has been reported on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 September 2008
28 April 2008
17 May 2013
© 2013 thepharmaletter.com